Press Release: Availability of the revised financial statements for Sanofi excluding Opella
06 Dezembro 2024 - 3:30AM
Availability of the revised financial statements
for Sanofi excluding Opella
Paris, France – December 6,
2024. Following the press release on October 21, 2024 and
the plan to transfer a 50% controlling stake in Opella (consumer
healthcare division) to CD&R, the revised financial statements
for Sanofi reflecting the new scope, excluding Opella, are now
available on the "Investors" section of sanofi.com in one
convenient spreadsheet file.
The adjustments to the financial statements
reclassify Opella’s business as discontinued operations, in line
with the planned transition of Sanofi to a focused, science-driven
biopharma company.
The revised financial data which were reviewed
by Sanofi’s auditors, include details on sales, business net income
and reported IFRS financials of Sanofi excluding Opella. From Q4
2024 and until the closing of the transaction, the profit or loss
of Opella, net of tax, is included in “Net income / (loss) from
discontinued operations” in the Sanofi income statement. This
classification as discontinued operations as well as the full
financial data apply to all previous quarters of 2024 and for
comparison to all quarters of 2023.
Sanofi's Q4 2024 results, reflecting the new
scope excluding Opella, are expected to be published
on January 30, 2025.
About Sanofi We are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comEvan Berland |
+ 1 215 432 0234 | evan.berland@sanofi.comLéo Le
Bourhis | + 33 6 75 06 43 81
| leo.lebourhis@sanofi.comNicolas
Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com Timothy Gilbert |
+ 1 516 521 2929 | timothy.gilbert@sanofi.com
Investor RelationsThomas Kudsk
Larsen | + 44 75 45 51 36 93|
thomas.larsen@sanofi.comAlizé Kaisserian | + 33 6
47 04 12 11 | alize.kaisserian@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comKeita Browne | +1 781 249
1766 | keita.browne@sanofi.comNathalie Pham | + 33
7 85 93 30 17 | nathalie.pham@sanofi.comTarik
Elgoutni | + 1 617 710 3587 |
tarik.elgoutni@sanofi.comThibaud Châtelet | + 33 6
80 80 89 90 | thibaud.chatelet@sanofi.com
Forward-looking statementsThis
press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions, and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that pandemics or other
global crises may have on us, our customers, suppliers, vendors,
and other business partners, and the financial condition of any one
of them, as well as on our employees and on the global economy as a
whole. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2023. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
